Ultrasome

Ultrasome is a proprietary cell-free regenerative therapy developed by Creative Medical Technology Holdings, Inc. for the treatment of knee osteoarthritis. Derived from the company's GMP-manufactured cell therapy product CELZ-201 (Olastrocel), Ultrasome is designed as a biologic modality that delivers biologically active regenerative signals through a minimally invasive procedure. Its mechanism of action targets osteoarthritis by modulating inflammatory signaling, suppressing cartilage degradation, and promoting regenerative activity within the joint. As a cell-free format, it is engineered to enable scalable manufacturing, reduced production costs, off-the-shelf availability, and simplified administration in outpatient settings compared to traditional cell-based therapies. A pilot study demonstrated a 93% response rate, with patients showing significant improvements in mobility and pain reduction without serious adverse events.

Brand names

Ultrasome